A Phase 1, Open-Label, Dose-Escalation Study of PRT1419, a Selective Induced Myeloid Leukemia Cell Differentiation Protein (MCL-1) Inhibitor, in Patients (pts) with Advanced/metastatic Solid Tumors
CANCER RESEARCH(2023)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined